Jubilant Pharmova (JUBLPHARMA) — concall transcript

📢 Key Event
Jubilant Pharmova's Q3 FY23 profit declined sharply due to radiopharmacy losses and margin pressure in generics and API businesses.

🔄 What Changed
Net profit turned negative at ₹-16 crores, EBITDA fell to ₹155 crores, and radiopharmacy losses are expected to normalize by Q4 FY23.

🔮 What's Next
Management targets breakeven in generics by FY24 end and aims for double-digit growth in CRDMO starting end of FY24.

💡 Investor Takeaway
The company is navigating near-term profitability pressures but is focused on cost reduction and long-term growth in CRDMO and Radiopharma.

Jubilant Pharmova reported Q3 FY23 revenue of ₹1,553 crores, up from ₹1,311 crores YoY but down sequentially from ₹1,600 crores, with EBITDA falling to ₹155 crores from ₹200 crores YoY and ₹232 crores QoQ. Net profit turned negative at ₹-16 crores versus ₹51 crores YoY and ₹5 crores QoQ, driven by radiopharmacy losses from a Mo-99 shortage and margin pressure in generics and API businesses. Capex stood at [amount context mismatch] crores in Q3, with net debt rising to ₹2,407 crores by December 2022. Management expects radiopharmacy losses to normalize by Q4, targets breakeven in generics by FY24 end, and plans ₹150 crores in cost savings by March '23 plus an additional ₹50 crores from Q1 FY24, while advancing clinical programs for potential capital raise or licensing by year-end.

📄 View Original Announcement (PDF)

📊 Stock Analysis — JUBLPHARMA ✨ Ask AI About This

About Jubilant Pharmova Ltd (JUBLPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹14,423.7 Cr P/E: 40.7 ROE: 5.0% ROCE: 7.4% Div Yield: 0.55%

View full JUBLPHARMA stock details →

📡 Get AI alerts when JUBLPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track JUBLPHARMA — Free

💡 Ask AI about this filing

"When will radiopharmacy margins fully recover?" "What is the timeline for API margin improvement?" "How will the ₹150 crores cost savings be achieved?"

Ask AI Free →

📊 More JUBLPHARMA filings

See all JUBLPHARMA filings →

🔥 Also filed on 31 December 2022

M&M Mahindra & Mahindra Ltd concall transcript INFY Infosys Ltd concall transcript ASIANPAINT Asian Paints Ltd concall transcript RELIANCE Reliance Industries Ltd concall transcript TATASTEEL Tata Steel Ltd concall transcript

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JUBLPHARMA files new disclosures

Track JUBLPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JUBLPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd